MedTrace Logo

Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

NCT04263922 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 466

Last updated 2024-07-12

No results posted yet for this study

Summary

This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.

Conditions

  • Renal Insufficiency, Chronic

Interventions

DRUG

Huaiqihuang granules

Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.

DRUG

Valsartan capsule

Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    collaborator OTHER

  • LinkDoc Technology (Beijing) Co. Ltd.

    collaborator INDUSTRY

  • The First Affiliated Hospital of Dalian Medical University

    lead OTHER

Principal Investigators

  • Hongli Lin, MD · The First Affiliated Hospital of Dalian Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2025-10-31
Completion
2026-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04263922 on ClinicalTrials.gov